BR112017010471A2 - compostos de di-hidropirimidin-2-ona e usos médicos dos mesmos - Google Patents

compostos de di-hidropirimidin-2-ona e usos médicos dos mesmos

Info

Publication number
BR112017010471A2
BR112017010471A2 BR112017010471A BR112017010471A BR112017010471A2 BR 112017010471 A2 BR112017010471 A2 BR 112017010471A2 BR 112017010471 A BR112017010471 A BR 112017010471A BR 112017010471 A BR112017010471 A BR 112017010471A BR 112017010471 A2 BR112017010471 A2 BR 112017010471A2
Authority
BR
Brazil
Prior art keywords
compounds
dihydropyrimidin
medical uses
symbol
formula
Prior art date
Application number
BR112017010471A
Other languages
English (en)
Other versions
BR112017010471B1 (pt
Inventor
Watanabe Eiichi
Suwa Katsunori
Maeda Katsuya
Shiozaki Makoto
Yokota Masahiro
Noguchi Masato
Seki Noriyoshi
Fujioka Shingo
Sakai Takayuki
Ikenogami Taku
Ogoshi Yosuke
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of BR112017010471A2 publication Critical patent/BR112017010471A2/pt
Publication of BR112017010471B1 publication Critical patent/BR112017010471B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C265/00—Derivatives of isocyanic acid
    • C07C265/02—Derivatives of isocyanic acid having isocyanate groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/12—Organo silicon halides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

compostos representados por fórmula [i] ou sais farmaceuticamente aceitáveis dos mesmos: em que cada símbolo é como definido na descrição.
BR112017010471-7A 2014-12-12 2015-12-11 Compostos de di-hidropirimidin-2-ona, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos BR112017010471B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014-251771 2014-12-12
JP2014251771 2014-12-12
PCT/JP2015/084791 WO2016093342A1 (ja) 2014-12-12 2015-12-11 ジヒドロピリミジン－２－オン化合物およびその医薬用途

Publications (2)

Publication Number Publication Date
BR112017010471A2 true BR112017010471A2 (pt) 2017-12-26
BR112017010471B1 BR112017010471B1 (pt) 2024-02-27

Family

ID=56107519

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017010471-7A BR112017010471B1 (pt) 2014-12-12 2015-12-11 Compostos de di-hidropirimidin-2-ona, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos

Country Status (33)

Country Link
US (4) US10196363B2 (pt)
EP (2) EP3744713A1 (pt)
JP (4) JP6757565B2 (pt)
KR (1) KR102551018B1 (pt)
CN (1) CN107001286B (pt)
AR (1) AR102972A1 (pt)
AU (1) AU2015362394C1 (pt)
BR (1) BR112017010471B1 (pt)
CA (1) CA2965804C (pt)
CL (1) CL2017001467A1 (pt)
CO (1) CO2017005732A2 (pt)
CY (1) CY1122971T1 (pt)
DK (1) DK3231793T3 (pt)
ES (1) ES2787700T3 (pt)
HR (1) HRP20200584T1 (pt)
HU (1) HUE048503T2 (pt)
IL (2) IL251940B (pt)
LT (1) LT3231793T (pt)
ME (1) ME03760B (pt)
MX (1) MX371128B (pt)
MY (1) MY193671A (pt)
PE (1) PE20171119A1 (pt)
PH (1) PH12017501071A1 (pt)
PL (1) PL3231793T3 (pt)
PT (1) PT3231793T (pt)
RS (1) RS60352B1 (pt)
RU (1) RU2770061C2 (pt)
SA (1) SA517381678B1 (pt)
SG (2) SG11201703885TA (pt)
SI (1) SI3231793T1 (pt)
TW (2) TWI739206B (pt)
WO (1) WO2016093342A1 (pt)
ZA (1) ZA201703976B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI739206B (zh) * 2014-12-12 2021-09-11 日商日本煙草產業股份有限公司 二氫嘧啶-２-酮化合物及其醫藥用途
CN106496008A (zh) * 2016-10-20 2017-03-15 上海毕得医药科技有限公司 一种合成4‑(4‑氯苯基)环己酮的方法
MX2020008929A (es) * 2018-02-28 2020-10-01 Japan Tobacco Inc Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico.
KR20200126973A (ko) 2018-02-28 2020-11-09 니뽄 다바코 산교 가부시키가이샤 4-메틸디히드로피리미디논 화합물 및 그의 의약 용도
CN110294762B (zh) * 2019-06-14 2020-12-15 深圳市疾病预防控制中心（深圳市卫生检验中心、深圳市预防医学研究所） 检测米酵菌酸中毒的人工抗原及应用
WO2021149786A1 (en) 2020-01-24 2021-07-29 Japan Tobacco Inc. Methods of treating cancer using dihydropyrimidin-2-one compounds
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485107A (en) * 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
EP1962855B1 (en) * 2005-12-22 2013-08-21 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
DE102006031314A1 (de) * 2006-07-01 2008-01-03 Bayer Healthcare Aktiengesellschaft Verwendung von 1,4-Diaryl-dihydropyrimidin-2-on-Derivaten zur Behandlung der pulmonalen arteriellen Hyptertonie
MX2010001195A (es) 2007-08-09 2010-03-01 Hoffmann La Roche Derivados de benzoil-peperidina como moduladores dobles de los receptores 5-ht2a y d3.
WO2009150668A1 (en) * 2008-06-13 2009-12-17 Delhi University Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same
BR112013027670B1 (pt) 2011-04-28 2021-11-09 Japan Tobacco Inc Composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory
EP2682389A1 (en) 2012-07-02 2014-01-08 Commissariat A L'energie Atomique Et Aux Energies Alternatives Dihydropyrimidin-2(1H)-ones and dihydropyrimidin-2(1H)-thiones as inhibitors of sodium iodide symporter
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
US20160137639A1 (en) * 2012-10-26 2016-05-19 Japan Tobacco Inc. Triazole-isoxazole compound and medical use thereof
CN103113308B (zh) * 2013-01-25 2014-11-19 浙江大学 一种制备二氢嘧啶酮衍生物的方法
MA41148A (fr) 2014-12-12 2017-10-17 H Lundbeck As Procédé de fabrication d'idalopirdine
TWI739206B (zh) * 2014-12-12 2021-09-11 日商日本煙草產業股份有限公司 二氫嘧啶-２-酮化合物及其醫藥用途
KR20170095964A (ko) 2014-12-12 2017-08-23 에이스틸론 파마수티컬스 인코포레이티드 Hdac1/2 억제제로서 피페리딘 유도체
KR20170090499A (ko) 2014-12-12 2017-08-07 메르크 파텐트 게엠베하 Ｅｇｆｒ 억제제와 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체의 조합
SG11201704523WA (en) 2014-12-12 2017-07-28 H Lundbeck As A process for the manufacture of idalopirdine

Also Published As

Publication number Publication date
JP6757565B2 (ja) 2020-09-23
CL2017001467A1 (es) 2018-01-05
US20230373932A1 (en) 2023-11-23
HRP20200584T1 (hr) 2020-07-10
CA2965804A1 (en) 2016-06-16
PH12017501071A1 (en) 2017-12-18
EP3744713A1 (en) 2020-12-02
SA517381678B1 (ar) 2021-12-14
DK3231793T3 (da) 2020-05-11
RU2017124423A (ru) 2019-01-15
CA2965804C (en) 2023-10-10
IL251940A0 (en) 2017-06-29
EP3231793A1 (en) 2017-10-18
US20190359575A1 (en) 2019-11-28
LT3231793T (lt) 2020-04-27
WO2016093342A1 (ja) 2016-06-16
HUE048503T2 (hu) 2020-07-28
AR102972A1 (es) 2017-04-05
ES2787700T3 (es) 2020-10-16
AU2015362394A1 (en) 2017-05-25
PE20171119A1 (es) 2017-08-08
EP3231793B1 (en) 2020-03-11
JP2024133646A (ja) 2024-10-02
AU2015362394C1 (en) 2021-01-28
RU2770061C2 (ru) 2022-04-14
TWI739206B (zh) 2021-09-11
RS60352B1 (sr) 2020-07-31
CO2017005732A2 (es) 2017-08-31
MX2017007577A (es) 2017-09-28
PL3231793T3 (pl) 2020-07-27
SG10202010291VA (en) 2020-11-27
IL283335B (en) 2022-04-01
MY193671A (en) 2022-10-24
ME03760B (me) 2021-04-20
AU2015362394B2 (en) 2020-07-02
IL283335A (en) 2021-07-29
BR112017010471B1 (pt) 2024-02-27
TWI690515B (zh) 2020-04-11
PT3231793T (pt) 2020-05-06
JP2022116239A (ja) 2022-08-09
US20160194290A1 (en) 2016-07-07
TW202012377A (zh) 2020-04-01
ZA201703976B (en) 2019-06-26
JP2020200339A (ja) 2020-12-17
RU2017124423A3 (pt) 2019-08-13
US20210130300A1 (en) 2021-05-06
CN107001286B (zh) 2020-07-07
CY1122971T1 (el) 2021-10-29
SI3231793T1 (sl) 2020-07-31
US10196363B2 (en) 2019-02-05
KR20170090497A (ko) 2017-08-07
KR102551018B1 (ko) 2023-07-05
IL251940B (en) 2021-06-30
CN107001286A (zh) 2017-08-01
EP3231793A4 (en) 2018-09-19
JP2016113455A (ja) 2016-06-23
TW201639820A (zh) 2016-11-16
MX371128B (es) 2020-01-17
NZ731607A (en) 2024-03-22
SG11201703885TA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
BR112017010471A2 (pt) compostos de di-hidropirimidin-2-ona e usos médicos dos mesmos
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
BR112017005314A2 (pt) inibidores de ssao derivados de imidazo[4,5-c]piridina
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
BR112016017317A2 (pt) composto, antagonista de trpa1, medicamento, e, uso de um composto
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
DK3003307T3 (da) Kombinationsterapi omfattende oxazolidinon-quinoloner til anvendelse i behandling af bakterieinfektioner
BR112016006388A2 (pt) inibidor seletivo da fosfatidilinositol 3-quinase gama
DK3100747T3 (da) Steriliseret arbejdssystem
BR112017028549A2 (pt) derivados de pirimidina como inibidores de btk e usos dos mesmos
BR112016027691A2 (pt) Composto de tetra-hidropiridopirimidina e seus usos
BR112016016130A2 (pt) Compostos e métodos
BR112017007194A2 (pt) compostos de hidroxil purina e aplicações dos mesmos
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
BR112016023490A2 (pt) uso de oxo tetrahidroquinolina sulfonamidas substituídas ou sais das mesmas para elevar a tolerância a estresse em plantas.
BR112017003231A2 (pt) compostos heterobicíclicos e seu uso para o tratamento da tuberculose
BR112016027383A2 (pt) Derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
EA201690075A1 (ru) Способ лечения внутриклеточной инфекции
BR112015016033A8 (pt) composições farmacêuticas para tratamento de infecções por bactérias, e seus usos
BR112018072039A2 (pt) composto, medicamento, método, e, uso do composto ou sal do mesmo
DK3065691T3 (da) Steril engangsbeholder med en aftagelig fastgørelsesindretning

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: JAPAN TOBACCO, INC. (JP)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/12/2015, OBSERVADAS AS CONDICOES LEGAIS